• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.040 -0.020 (-1.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
May 07, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024 ↗
May 06, 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 06, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Events
May 01, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for Pliant Therapeutics ↗
November 10, 2023
 
Via Benzinga
News headline image
Where Pliant Therapeutics Stands With Analysts ↗
October 04, 2023
 
Via Benzinga
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Events
April 02, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
March 27, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
March 12, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
February 27, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Conferences
February 26, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Events
February 07, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today? ↗
February 05, 2024
Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and secondary endpoints, showing well-tolerance and reduction in liver... 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know ↗
February 05, 2024
 
Via Benzinga
News headline image
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
February 04, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
February 05, 2024
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
News headline image
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
November 13, 2023
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Conferences
November 08, 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
November 06, 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
October 31, 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
October 19, 2023
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
October 16, 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
September 27, 2023
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market... 
Via Benzinga
News headline image
Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial ↗
September 26, 2023
Pliant Therapeutics Inc (NASDAQ: PLRX) announced data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected  
Via Benzinga
News headline image
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
September 26, 2023
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
News headline image
Why Shares of Pliant Therapeutics Are Rising Tuesday ↗
September 26, 2023
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions. 
Via The Motley Fool
News headline image
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗
September 26, 2023
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
September 26, 2023
Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap